These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38900249)

  • 41. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
    Johnston TH; Huot P; Fox SH; Wakefield JD; Sykes KA; Bartolini WP; Milne GT; Pearson JP; Brotchie JM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Bédard D; Frouni I; Kwan C; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Dec; 391(12):1339-1345. PubMed ID: 30088028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
    Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective blockade of the 5-HT
    Kwan C; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2021 Jan; 182():108386. PubMed ID: 33152452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
    Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
    J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain.
    Kim E; Frouni I; Shaqfah J; Bédard D; Huot P
    J Chem Neuroanat; 2024 Jul; 138():102422. PubMed ID: 38657828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
    Jackson MJ; Swart T; Pearce RK; Jenner P
    J Neural Transm (Vienna); 2014 Feb; 121(2):163-9. PubMed ID: 23959162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Viaro R; Marti M; Morari M
    Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. D
    Mailman RB; Yang Y; Huang X
    Eur J Pharmacol; 2021 Feb; 892():173760. PubMed ID: 33279520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    Iravani MM; Jackson MJ; Kuoppamäki M; Smith LA; Jenner P
    J Neurosci; 2003 Oct; 23(27):9107-15. PubMed ID: 14534244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
    Frouni I; Kang W; Bédard D; Belliveau S; Kwan C; Hadj-Youssef S; Bourgeois-Cayer É; Ohlund L; Sleno L; Hamadjida A; Huot P
    Eur J Pharmacol; 2022 Aug; 929():175090. PubMed ID: 35780824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor.
    Cid JM; Duvey G; Cluzeau P; Nhem V; Macary K; Raux A; Poirier N; Muller J; Boléa C; Finn T; Poli S; Epping-Jordan M; Chamelot E; Derouet F; Girard F; Macdonald GJ; Vega JA; de Lucas AI; Matesanz E; Lavreysen H; Linares ML; Oehlrich D; Oyarzábal J; Tresadern G; Trabanco AA; Andrés JI; Le Poul E; Imogai H; Lutjens R; Rocher JP
    ACS Chem Neurosci; 2010 Dec; 1(12):788-95. PubMed ID: 22778815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.